Bioceres Crop Solutions Reports Fiscal First Quarter 2026 Financial and Operational Results

Total revenues were $77.5 million in 1Q26

Net loss was $7.5 million and Adjusted EBITDA¹ was $13.6 million

ROSARIO, Argentina--(BUSINESS WIRE)-- Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal first quarter ended September 30, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.

Financial & Business Highlights

• Total revenues were $77.5 million in 1Q26, a 17% decline year over year, reflecting the expected reduction from the seed model transition and the pruning of low-margin and working-capital-intensive sales.
• Gross profit was $36.2 million, a 3% reduction from last year, with gross margin expanding to 47% from 40%, driven by a more profitable product mix.
• Operating profit was $7.1 million for the quarter, net loss was $7.5 million and Adjusted EBITDA¹ was $13.6 million. Operating profit and Adjusted EBITDA increased 200% and 61% year over year, respectively, reflecting margin expansion and cost discipline.
• Working capital continued to improve year over year and sequentially, despite first quarter’s seasonally high needs.

Management Review

Mr. Federico Trucco, Bioceres´ Chief Executive Officer, commented: “This quarter reflects clear progress on the priorities we set for the year: improve the quality of revenues, protect margins, and operate with discipline. Profitability improved and costs continued to decrease as we reduced exposure to low-margin activities and focused on a more efficient product mix. Argentina remains challenging, although conditions are showing early signs of normalization. In parallel, we are prioritizing actions that strengthen our capital structure and enhance financial flexibility. We will continue to focus on the fundamentals we control — margin quality, cost discipline, and working-capital efficiency — while positioning the Company for long-term resilience.”

Key Financial Metrics
Table 1: 1Q26 Key Financial Metrics

(In millions of U.S. dollars)	1Q25	1Q26	%CHANGE
Revenue by Segment
Crop Protection	47.7	39.9	(16 %)
Seed and Integrated Products	19.8	12.6	(37%)
Crop Nutrition	25.7	25.1	(2%)
Total Revenue	93.2	77.5	(17%)
Gross Profit	37.5	36.2	(3%)
Gross Margin	40.2%	46.7%	651 bps

	1Q25	1Q26	%CHANGE
GAAP Net income or loss	(6.2)	(7.5)	(21%)
Adjusted EBITDA1	8.5	13.6	61%

1Q26 Summary: Revenues totaled $77.5 million in 1Q26, a 17% decline versus the prior year. Revenue performance reflects both the planned reduction of low-margin and working-capital-intensive sales, as part of the strategic reset, and the impact of timing of sales in certain Latam markets, particularly Uruguay. In Argentina, while demand for select products showed improvement versus an unusually weak prior year, the recovery remains gradual.

Despite lower revenues, operating performance strengthened, supported by a more profitable product mix and lower operating expenses. Gross margin expanded significantly from 40% to 47%, and SG&A expenses decreased meaningfully year over year, reflecting restructuring initiatives and continued cost discipline.

Net loss was $7.5 million, compared to a loss of $6.2 million in 1Q25. Operating performance improved year over year, but higher financial costs and increased tax accruals led to a wider bottom-line loss. Adjusted EBITDA¹ was $13.6 million, a 61% increase versus $8.5 million in 1Q25, driven by gross margin expansion and a reduction in operating costs.

For a full version of Bioceres’ first quarter 2026 earnings release, click here

1 Please refer to the “Use of non IFRS financial information” section at this end of this document on our use of Adjusted EBITDA and its reconciliation to the most comparable IFRS financial measure.

Fiscal First Quarter 2026 Earnings Conference Call

Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website.

To access the call, please use the following information:

	Date: Thursday, November 13, 2025		Please dial in 5-10 minutes prior to the start time to register and join. The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.   A replay of the call will be available through November 20, 2025, following the conference. Toll Free Replay Number: 1-866-813-9403 International Replay Number: Click here   Replay ID: 616167
	Time: 8:30 a.m. EST, 5:30 a.m. PST
	US Toll Free dial-in number: 1-833-470-1428
	International dial-in numbers: Click here
	Conference ID: 925241
	Webcast: Click here

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. 

The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

Unaudited Consolidated Statement of Comprehensive Income
(Figures in million of U.S. dollars)

	Three-month period ended 09/30/2025	Three-month period ended 09/30/2024
Revenues from contracts with customers	77.3	92.6
Initial recognition and changes in the fair value of biological assets at the point of harvest	0.2	0.7
Cost of sales	(41.3)	(55.8)
Gross profit	36.2	37.5
% Gross profit	47%	40%
Operating expenses	(28.9)	(34.6)
Share of profit of JV	0.3	(0.6)
Change in net realizable value of agricultural products	(0.3)	0.6
Other income or expenses, net	(0.2)	(0.5)
Operating profit	7.1	2.4
Financial result	(12.6)	(9.8)
Profit/(loss) before income tax	(5.5)	(7.5)
Income tax	(2.1)	1.3
Profit/(loss) for the period	(7.5)	(6.2)
Other comprehensive loss	(0.3)	(0.0)
Total comprehensive profit/(loss)	(7.8)	(6.2)
Profit/(loss) for the period attributable to:
Equity holders of the parent	(7.4)	(6.4)
Non-controlling interests	(0.1)	0.2
	(7.5)	(6.2)
Total comprehensive profit/(loss) attributable to:
Equity holders of the parent	(7.7)	(6.4)
Non-controlling interests	(0.1)	0.2
	(7.8)	(6.2)

Weighted average number of shares
Basic	63.4	62.8
Diluted	63.4	62.8

Unaudited Consolidated Statement of Financial Position
(Figures in million of U.S. dollars)

ASSETS	9/30/2025	06/30/2025
CURRENT ASSETS
Cash and cash equivalents	15.5	32.7
Other financial assets	1.1	2.0
Trade receivables	158.4	165.9
Other receivables	16.6	15.9
Recoverable income tax	1.7	1.9
Inventories	88.6	87.6
Biological assets	1.2	2.4
Total current assets	283.2	308.3
NON-CURRENT ASSETS
Trade receivables	5.1	2.5
Other receivables	20.4	23.7
Recoverable income tax	0.0	0.0
Deferred tax assets	5.4	4.9
Investments in joint ventures and associates	39.4	39.4
Investment properties	0.6	0.6
Property, plant and equipment	74.0	74.6
Intangible assets	178.6	181.2
Goodwill	112.2	112.2
Right of use asset	15.8	16.4
Total non-current assets	451.7	455.3
Total assets	734.8	763.6
LIABILITIES
CURRENT LIABILITIES
Trade and other payables	107.1	96.4
Borrowings	85.1	119.7
Employee benefits and social security	5.5	6.2
Deferred revenue and advances from customers	2.3	4.3
Income tax payable	3.0	0.5
Consideration for acquisition	0.8	1.8
Secured notes	103.6	102.3
Lease liabilities	3.8	6.9
Total current liabilities	311.3	338.0
NON-CURRENT LIABILITIES
Trade and other payables	36.9	48.5
Borrowings	53.8	38.2
Deferred revenue and advances from customers	1.8	1.4
Joint ventures and associates	0.8	1.0
Deferred tax liabilities	28.3	30.1
Provisions	1.2	1.3
Consideration for acquisition	0.4	0.4
Lease liabilities	12.2	9.5
Total non-current liabilities	135.3	130.4
Total liabilities	446.5	468.4
EQUITY
Equity attributable to owners of the parent	258.6	265.4
Non-controlling interests	29.7	29.8
Total equity	288.3	295.2
Total equity and liabilities	734.8	763.6

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112632105/en/

Bioceres Crop Solutions

Paula Savanti

Head of Investor Relations

investorrelations@biocerescrops.com

Source: Bioceres Crop Solutions Corp.